Movatterモバイル変換


[0]ホーム

URL:


PH12018500221A1 - A prolonged release dosage form comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof in the treatment of bladder pain syndrome (bps) - Google Patents

A prolonged release dosage form comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof in the treatment of bladder pain syndrome (bps)

Info

Publication number
PH12018500221A1
PH12018500221A1PH12018500221APH12018500221APH12018500221A1PH 12018500221 A1PH12018500221 A1PH 12018500221A1PH 12018500221 APH12018500221 APH 12018500221APH 12018500221 APH12018500221 APH 12018500221APH 12018500221 A1PH12018500221 A1PH 12018500221A1
Authority
PH
Philippines
Prior art keywords
pharmaceutically acceptable
acceptable salt
naloxone
oxycodone
bps
Prior art date
Application number
PH12018500221A
Inventor
Michael Hopp
Wolfram Kremers
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SafiledCriticalEuro Celtique Sa
Publication of PH12018500221A1publicationCriticalpatent/PH12018500221A1/en

Links

Classifications

Landscapes

Abstract

The present invention provides a pharmaceutical dosage form comprising oxycodone and naloxone (or pharmaceutically acceptable salts thereof) for use in the treatment of Bladder Pain Syndrome (BPS) and/or at least one, preferably at least two symptoms thereof.
PH12018500221A2015-07-312018-01-29A prolonged release dosage form comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof in the treatment of bladder pain syndrome (bps)PH12018500221A1 (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
EP151792852015-07-31
PCT/EP2016/068173WO2017021304A1 (en)2015-07-312016-07-29A prolonged release dosage form comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof in the treatment of bladder pain syndrome (bps)

Publications (1)

Publication NumberPublication Date
PH12018500221A1true PH12018500221A1 (en)2018-07-30

Family

ID=53776411

Family Applications (1)

Application NumberTitlePriority DateFiling Date
PH12018500221APH12018500221A1 (en)2015-07-312018-01-29A prolonged release dosage form comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof in the treatment of bladder pain syndrome (bps)

Country Status (5)

CountryLink
EP (1)EP3328386A1 (en)
AU (1)AU2016301861A1 (en)
BR (1)BR112018001504A2 (en)
PH (1)PH12018500221A1 (en)
WO (1)WO2017021304A1 (en)

Also Published As

Publication numberPublication date
BR112018001504A2 (en)2018-09-11
EP3328386A1 (en)2018-06-06
WO2017021304A1 (en)2017-02-09
AU2016301861A1 (en)2018-02-22

Similar Documents

PublicationPublication DateTitle
IL288231A (en)An inhibitor of jak1/2 or a pharmaceutically acceptable salt thereof and an inhibitor of pi3k or a pharmaceutically acceptable salt thereof, for use in the treatment of myelofibrosis
PH12018502109A1 (en)Medicine obtained by combining fxr agonist and arb
HK1223319A1 (en)Methods for treating or preventing ophthalmological conditions
PH12017502431A1 (en)Pharmaceutical formulations comprising tenofovir and emtrictabine
MX384403B (en) COMBINATION THERAPY FOR THE TREATMENT OF CANCER.
MX2016012574A (en)Substituted heteroaryl compounds and methods of use.
MX383665B (en) COMPOSITIONS OF DONEPEZIL AND METHODS FOR TREATING ALZHEIMER'S DISEASE.
MX2017016802A (en)Pharmaceutical formulations.
MX2017009416A (en)Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function.
PH12016502233A1 (en)(s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
EA201692111A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DANIRYXIN FOR TREATING INFECTIOUS DISEASES
PH12016500666A1 (en)Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
CY1119522T1 (en) (R) - PILINDOL AND THE PHARMACEUTICALALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
PT3215143T (en)Combination comprising spirulina and palmitoylethanolamide and/or salts or pharmaceutically acceptable derivatives thereof and their formulations, for use in the prevention and/or in the treatment of hyperactivated tissue conditions
ZA201802399B (en)Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use in the treatment of cancer
PH12018500221A1 (en)A prolonged release dosage form comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof in the treatment of bladder pain syndrome (bps)
PH12016502107A1 (en)Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
IL248428B (en)1,3-propanedisulfonic acid or pharmaceutically acceptable salts thereof for use in the treatment of sarcoidosis
PH12016501975A1 (en)New use of n,n-bis-2-mercaptoethyl isophthalamide
HRP20211309T1 (en) N, N-BIS-2-MERKAPTOETYL ISOPHTALAMIDE FOR THE TREATMENT OF PARKINSON'S DISEASE
ZA201600894B (en)Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes
HK1231763A1 (en)Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
MX2016010919A (en)4-benzylsulfonyl-2-butenenitrile.
AR100910A1 (en) ORAL DOSAGE FORM OF SUSTAINED RELEASE CONTAINING MORPHINE AND NALOXONE

[8]ページ先頭

©2009-2025 Movatter.jp